#USA #San Diego #Crystalys Therapeutics #dotinurad #Justin Thacker

Crystalys Therapeutics Welcomes a New CFO

In a significant move aimed at advancing its groundbreaking gout treatment, Crystalys Therapeutics, Inc. has appointed Justin Thacker as its new Chief Financial Officer (CFO). This announcement comes as the biopharmaceutical company prepares to initiate Phase 3 clinical trials for its lead candidate, Dotinurad.

Exciting Times at Crystalys

James M. Mackay, the CEO and President of Crystalys, expressed his enthusiasm about Thacker's appointment, citing his extensive experience and exemplary track record in financial management and strategic transactions as key assets for the company. “We’re incredibly excited to welcome Justin to our executive team,” he stated. Mackay believes that Thacker’s contributions will be crucial as the company progresses with its clinical trials and regulatory approvals for Dotinurad, which aims to fulfill significant medical needs for gout patients.

Thacker expressed his own excitement about joining Crystalys, particularly at this pivotal stage in the company's journey. “The initiation of our Phase 3 trials, RUBY and TOPAZ, evaluating dotinurad as a potential best-in-class gout therapy, together with the momentum from our $205 million Series A financing, marks a transformative moment for the Company,” he said.

Thacker’s Impressive Background

Justin Thacker brings over 25 years of finance leadership experience, notably in the life sciences sector, spanning both private and public companies. His impressive portfolio includes successful positions at various biopharma organizations, where he played integral roles in initial public offerings (IPOs), product launches, and mergers and acquisitions. Most recently, Thacker served as CFO at Capstan Therapeutics, where he navigated rapid growth leading to the company’s acquisition by AbbVie for up to $2.1 billion. His previous roles include significant positions at Aristea Therapeutics, Design Therapeutics, and Synthorx (acquired by Sanofi).

Thacker began his career with PricewaterhouseCoopers LLP, and holds both a Master of Accountancy and a Bachelor of Science in Accounting and General Management from Kansas State University. His credentials as a Certified Public Accountant in Missouri provide further assurance of his qualifications as CFO.

Dotinurad: A Game-Changing Treatment

Crystalys Therapeutics is at the forefront of innovation in gout treatment. With its headquarters in San Diego, California, the company is dedicated to offering improved drug options for gout patients. Dotinurad, the company’s flagship product, is designed as a next-generation, once-daily oral URAT1 inhibitor, which gained regulatory approval in several Asian markets, including Japan, China, Philippines, and Thailand. The drug targets uric acid reduction, gout flares, and tophi, aiming for a safer and more effective treatment option.

The company is now rushing toward global Phase 3 trials, with substantial backing from its recent funding efforts, paving the way for future regulatory approval and commercial launch. These trials are set to evaluate its efficacy against established standards for gout therapy. The commitment to advancing Dotinurad underscores Crystalys' mission to improve patient care for individuals suffering from gout.

As Crystalys Therapeutics embarks on this new phase with Justin Thacker steering financial strategies, the healthcare community eagerly anticipates the impact on gout treatment options that Dotinurad could bring. To learn more about this innovative company and its commitment to transforming gout therapy, visit Crystalys Therapeutics or follow their updates on social media platforms.